Claudia Fish, MD
Endocrinology, Diabetes & Metabolism · Park City, UTNPI 1043293665
Payments from drug & device makers
Across 729 payments — averaging $392.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$237K
- AstraZeneca$45K
- Novo Nordisk$707
- Amgen$613
- Chiesi USA, Inc.$346
- Sanofi-aventis U.S. LLC$267
- plus $2K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 480 | $237,451 |
| AstraZeneca(2 entities) | 71 | $44,871 |
| Novo Nordisk | 28 | $707 |
| Amgen(2 entities) | 26 | $613 |
| Chiesi USA, Inc. | 2 | $346 |
| Sanofi-aventis U.S. LLC | 16 | $267 |
| AbbVie | 8 | $252 |
| Pfizer | 11 | $216 |
| Merck | 11 | $170 |
| Medtronic(2 entities) | 7 | $133 |
| Dexcom, Inc. | 6 | $117 |
| Radius Health, Inc. | 6 | $115 |
| Amarin Pharma, Inc. | 5 | $113 |
| Insulet Corporation | 5 | $111 |
| Tandem Diabetes Care, Inc. | 6 | $108 |
| Ipsen Biopharmaceuticals, Inc | 5 | $101 |
| Mannkind Corporation | 4 | $101 |
| Abbott | 5 | $96 |
| Recordati_rare_diseases_inc. | 4 | $76 |
| Novartis | 4 | $72 |
| EUSA Pharma (US) LLC | 3 | $57 |
| Nestle Healthcare Nutrition Inc. | 3 | $48 |
| Boehringer Ingelheim | 3 | $46 |
| Corcept Therapeutics | 3 | $43 |
| Madrigal Pharmaceuticals | 1 | $42 |
| Johnson & Johnson | 2 | $31 |
| Ascendis Pharma Endocrinology Inc | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Bayer | 1 | $13 |
| Lifescan, Inc. | 1 | $12 |
How this compares
$286,370 in reported general payments places this provider in the 90th percentile of 38 endocrinology, diabetes & metabolism providers in Utah.
See all endocrinology, diabetes & metabolism providers in Utah →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Park City
- Jack WahlenOgden$1.5M
- Eliot BrintonSalt Lake City$822K
- Timothy GrahamSandy$541K
- Alireza Falahati-NiniSalt Lake City$251K
- Steven BrownLayton$105K
- Amnon SchlegelSandy$57K
- Mohammed NizamProvo$54K
- Debra SimmonsSalt Lake City$36K
- James GruaWest Valley City$33K
- Shahzad AhmadSalt Lake City$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.